Cost of care for patients with age-related macular degeneration in Switzerland and cost-effectiveness of treatment with verteporfin therapy

Seminars in Ophthalmology

Volumn 16, Issue 4, 2001, Pages 218-222

  Greiner, Roger Axel ^a  

^a NONE   (Switzerland)

Author keywords

Age related macular degeneration; Cost effectiveness; Verteporfin

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; STATISTICAL MODEL; SUBRETINAL NEOVASCULARIZATION; SWITZERLAND; VISUAL ACUITY; VISUAL IMPAIRMENT;

COST-BENEFIT ANALYSIS; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; SWITZERLAND; TREATMENT OUTCOME;

EID: 0035555466     PISSN: 08820538     EISSN: None     Source Type: Journal    
DOI: 10.1076/soph.16.4.218.10302     Document Type: Review

References (3)

1. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2
2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: Three-year results of an open-label extension of 2 randomized clinical trials - TAP Report No. 6
3. The cost-effectiveness of photodynamic therapy for fellow eyes with subfoveal choroidal neovascularization secondary to age-related macular degeneration